BICO Group AB engages in the provision of technologies, products, and services to create, understand, and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 589 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
最新の財務諸表(Form-10K)によると、Templeton Emerging Markets Fund Incの総資産は$0で、純損失は$0です。
BCCOYの主要な財務比率は何ですか?
Templeton Emerging Markets Fund Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
BICO Group AB (publ)の収益はセグメントまたは地域別にどのように分けられていますか?
Templeton Emerging Markets Fund Inc の最大収益セグメントは Gas, Water, Renewable Energy and Related Businesses で、最新の利益発表における収益は 53,884,300,000 です。地域別に見ると、China が Templeton Emerging Markets Fund Inc の主要市場であり、収益は 43,387,900,000 です。
BICO Group AB (publ)は収益を上げていますか?
いいえ、最新の財務諸表によると、Templeton Emerging Markets Fund Incの純損失は$0です。